Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Variations in biofilm formation, desiccation resistance and Benzalkonium chloride susceptibility among Listeria monocytogenes strains isolated in Canada.

Piercey MJ, Ells TC, Macintosh AJ, Truelstrup Hansen L.

Int J Food Microbiol. 2017 Sep 18;257:254-261. doi: 10.1016/j.ijfoodmicro.2017.06.025. Epub 2017 Jul 8.

PMID:
28710947
2.

Genes involved in Listeria monocytogenes biofilm formation at a simulated food processing plant temperature of 15 °C.

Piercey MJ, Hingston PA, Truelstrup Hansen L.

Int J Food Microbiol. 2016 Apr 16;223:63-74. doi: 10.1016/j.ijfoodmicro.2016.02.009. Epub 2016 Feb 11.

PMID:
26900648
3.

Genes Associated with Desiccation and Osmotic Stress in Listeria monocytogenes as Revealed by Insertional Mutagenesis.

Hingston PA, Piercey MJ, Truelstrup Hansen L.

Appl Environ Microbiol. 2015 Aug 15;81(16):5350-62. doi: 10.1128/AEM.01134-15. Epub 2015 May 29.

4.

Antimicrobial activity of cyclodextrin entrapped allyl isothiocyanate in a model system and packaged fresh-cut onions.

Piercey MJ, Mazzanti G, Budge SM, Delaquis PJ, Paulson AT, Truelstrup Hansen L.

Food Microbiol. 2012 May;30(1):213-8. doi: 10.1016/j.fm.2011.10.015. Epub 2011 Nov 2.

PMID:
22265303
5.

Patterns of genetic variation in Phialocephala fortinii across a broad latitudinal transect in Canada.

Piercey MM, Graham SW, Currah RS.

Mycol Res. 2004 Aug;108(Pt 8):955-64.

PMID:
15449601
6.
7.

Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase.

Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG, Hyslop DK, Piercey M, Wightman RM, Lawler CP, Nichols DE, Mailman RB.

J Pharmacol Exp Ther. 2002 Jun;301(3):1166-78.

PMID:
12023552
8.

Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.

Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, Hyslop DK, Franklin S, Porsolt RD, Bonsignori A, Carfagna N, McArthur RA.

Biol Psychiatry. 2000 May 1;47(9):818-29.

PMID:
10812041
9.

Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.

Bennett JP Jr, Piercey MF.

J Neurol Sci. 1999 Feb 1;163(1):25-31. Review.

PMID:
10223406
10.

The effects of (+)-UH232 and (-)-DS121 on local cerebral glucose utilization in rats.

Walker EL, Ray CA, Piercey MF.

J Neural Transm (Vienna). 1999;106(1):59-74.

PMID:
10195335
11.

Neurochemical and behavioral evidence supporting (+)-AJ 76 as a potential pharmacotherapy for cocaine abuse.

Broderick PA, Piercey MF.

J Neural Transm (Vienna). 1998;105(10-12):1307-24.

PMID:
9928899
13.

Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.

Piercey MF.

Clin Neuropharmacol. 1998 May-Jun;21(3):141-51. Review.

PMID:
9617505
14.

Excitation of type II anterior caudate neurons by stimulation of dopamine D3 receptors.

Piercey MF, Hyslop DK, Hoffmann WE.

Brain Res. 1997 Jul 11;762(1-2):19-28.

PMID:
9262154
15.

Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.

Heier RF, Dolak LA, Duncan JN, Hyslop DK, Lipton MF, Martin IJ, Mauragis MA, Piercey MF, Nichols NF, Schreur PJ, Smith MW, Moon MW.

J Med Chem. 1997 Feb 28;40(5):639-46.

PMID:
9057850
16.

Interactions between cocaine and (-)-DS 121: studies with 2-deoxyglucose autoradiography and microdialysis in the rat brain.

Koch S, Piercey MF, Galloway MP, Svensson KA.

Eur J Pharmacol. 1997 Jan 29;319(2-3):173-80.

PMID:
9042588
17.

Pharmacology of U-91356A, an agonist for the dopamine D2 receptor subtype.

Piercey MF, Moon MW, Sethy VH, Schreur PJ, Smith MW, Tang AH, Von Voigtlander PF.

Eur J Pharmacol. 1996 Dec 12;317(1):29-38.

PMID:
8982716
18.

Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.

Merchant KM, Gill GS, Harris DW, Huff RM, Eaton MJ, Lookingland K, Lutzke BS, Mccall RB, Piercey MF, Schreur PJ, Sethy VH, Smith MW, Svensson KA, Tang AH, Vonvoigtlander PF, Tenbrink RE.

J Pharmacol Exp Ther. 1996 Dec;279(3):1392-403.

PMID:
8968364
19.

High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum.

Piercey MF, Walker EL, Feldpausch DL, Camacho-Ochoa M.

Neurosci Lett. 1996 Nov 22;219(2):138-40.

PMID:
8971799
20.
21.

Excitation of type II caudate neurons by systemic administration of dopamine agonists.

Piercey MF, Hyslop DK, Hoffmann WE.

Brain Res. 1996 Jan 15;706(2):249-58.

PMID:
8822364
22.
23.

Rat brain binding sites for pramipexole, a clinically useful D3-preferring dopamine agonist.

Camacho-Ochoa M, Walker EL, Evans DL, Piercey MF.

Neurosci Lett. 1995 Aug 18;196(1-2):97-100.

PMID:
7501268
24.

Effect of (-)-DS 121 and (+)-UH 232 on cocaine self-administration in rats.

Smith A, Piercey M, Roberts DC.

Psychopharmacology (Berl). 1995 Jul;120(1):93-8.

PMID:
7480540
25.

Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.

Calon F, Goulet M, Blanchet PJ, Martel JC, Piercey MF, Bédard PJ, Di Paolo T.

Brain Res. 1995 May 22;680(1-2):43-52.

PMID:
7663983
26.

Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.

Blanchet PJ, Calon F, Martel JC, Bédard PJ, Di Paolo T, Walters RR, Piercey MF.

J Pharmacol Exp Ther. 1995 Feb;272(2):854-9.

PMID:
7853204
27.

Characterization of U-92016A as a selective, orally active, high intrinsic activity 5-hydroxytryptamine1A agonist.

McCall RB, Romero AG, Bienkowski MJ, Harris DW, McGuire JC, Piercey MF, Shuck ME, Smith MW, Svensson KA, Schreur PJ, et al.

J Pharmacol Exp Ther. 1994 Nov;271(2):875-83.

PMID:
7965808
28.

Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography.

Blin J, Piercey MF, Giuffra ME, Mouradian MM, Chase TN.

J Neurol Sci. 1994 May;123(1-2):44-51.

PMID:
8064320
29.

Excitation of noradrenergic cell firing by 5-hydroxytryptamine1A agonists correlates with dopamine antagonist properties.

Piercey MF, Smith MW, Lum-Ragan JT.

J Pharmacol Exp Ther. 1994 Mar;268(3):1297-303.

PMID:
8138943
30.

Pharmacology of a mixed 5-hydroxytryptamine1A/dopamine agonist.

Piercey MF, Tang AH, Lahti RA, VonVoigtlander PF, Schreur PJ, McCall RB, Lum-Ragan JT, Hoffmann WE, Franklin SR, Code RA, et al.

J Pharmacol Exp Ther. 1994 Mar;268(3):1304-10.

PMID:
7908053
31.

Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and position emission tomography.

Blin J, Ray CA, Piercey MF, Bartko JJ, Mouradian MM, Chase TN.

Brain Res. 1994 Jan 28;635(1-2):196-202.

PMID:
8173955
32.
33.

Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists.

Sonesson C, Waters N, Svensson K, Carlsson A, Smith MW, Piercey MF, Meier E, Wikström H.

J Med Chem. 1993 Oct 15;36(21):3188-96.

PMID:
8230107
34.

The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; a microdialysis study.

Waters N, Lagerkvist S, Löfberg L, Piercey M, Carlsson A.

Eur J Pharmacol. 1993 Sep 28;242(2):151-63.

PMID:
8253112
35.

Antagonism of cocaine self-administration by the preferential dopamine autoreceptor antagonist, (+)-AJ 76.

Richardson NR, Piercey MF, Svensson K, Collins RJ, Myers JE, Roberts DC.

Brain Res. 1993 Aug 13;619(1-2):15-21.

PMID:
8374772
36.

Evaluation of the reinforcing and discriminative stimulus effects of cocaine in combination with (+)-AJ76 or clozapine.

Vanover KE, Piercey MF, Woolverton WL.

J Pharmacol Exp Ther. 1993 Aug;266(2):780-9.

PMID:
8355207
37.

Synthesis and biological activity of cis-(3aR)-(-)-2,3,3a,4,5,9b-hexahydro- 3-propyl-1H-benz[e]indole-9-carboxamide: a potent and selective 5-HT1A receptor agonist with good oral availability.

Lin CH, Haadsma-Svensson SR, Phillips G, McCall RB, Piercey MF, Smith MW, Svensson K, Carlsson A, Chidester CG, Von Voigtlander PF.

J Med Chem. 1993 Jul 23;36(15):2208-18.

PMID:
8340922
38.
39.

Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.

Lin CH, Haadsma-Svensson SR, Phillips G, Lahti RA, McCall RB, Piercey MF, Schreur PJ, Von Voigtlander PF, Smith MW, Chidester CG.

J Med Chem. 1993 Apr 16;36(8):1069-83.

PMID:
8097538
40.

Centrally acting serotonergic and dopaminergic agents. 1. Synthesis and structure-activity relationships of 2,3,3a,4,5,9b-hexahydro-1H-benz[e]indole derivatives.

Lin CH, Haadsma-Svensson SR, Lahti RA, McCall RB, Piercey MF, Schreur PJ, Von Voigtlander PF, Smith MW, Chidester CG.

J Med Chem. 1993 Apr 16;36(8):1053-68.

PMID:
8097537
41.

Centrally acting serotonergic agents. Synthesis and structure-activity relationships of C-1- or C-3-substituted derivatives of 8-hydroxy-2-(di-n-propylamino)tetralin.

Lin CH, Haadsma-Svensson SR, Lahti RA, McCall RB, Piercey MF, Schreur PJ, VonVoigtlander PF, Chidester CG.

J Med Chem. 1993 Mar 19;36(6):671-82.

PMID:
8459396
42.

Effects of cholinergic agonists on regional brain energy metabolism in the scopolamine-treated rat.

Ray CA, Blin J, Chase TN, Piercey MF.

Neuropharmacology. 1992 Nov;31(11):1193-9.

PMID:
1475026
43.
44.

Antagonism of cocaine's pharmacological effects by the stimulant dopaminergic antagonists, (+)-AJ76 and (+)-UH232.

Piercey MF, Lum JT, Hoffmann WE, Carlsson A, Ljung E, Svensson K.

Brain Res. 1992 Aug 21;588(2):217-22.

PMID:
1393576
45.

Novel indolodioxanes with antihypertensive effects: potent ligands for the 5-HT1A receptor.

Ennis MD, Baze ME, Smith MW, Lawson CF, McCall RB, Lahti RA, Piercey MF.

J Med Chem. 1992 Aug 7;35(16):3058-66.

PMID:
1323682
46.

Dopaminergic and serotonergic activities of imidazoquinolinones and related compounds.

Moon MW, Morris JK, Heier RF, Chidester CG, Hoffmann WE, Piercey MF, Althaus JS, Von Voigtlander PF, Evans DL, Figur LM, et al.

J Med Chem. 1992 Mar 20;35(6):1076-92.

PMID:
1348089
47.
48.

Intrinsic activity of DA agonists.

Lahti RA, Figur LM, Piercey MF, Ruppel PL, Evans DL.

Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:182A-183A. No abstract available.

PMID:
1354024
49.

Effect of the anticonvulsant U-54494A on cortical neuron excitability: comparison to the kappa agonist U-50488H.

Ochoa MC, Vogelsang GD, Lum JT, VonVoigtlander PF, Piercey MF.

Life Sci. 1992;50(17):1225-33.

PMID:
1349150
50.

U-54494A reduces 4-AP-induced afterdischarges of CA1 pyramidal cells in the hippocampal slice of the rat.

Camacho-Ochoa M, VonVoigtlander PF, Hoffmann WE, Piercey MP.

Life Sci. 1992;50(6):457-63.

PMID:
1310340

Supplemental Content

Loading ...
Support Center